Oxaliplatin - Dr Reddy's Laboratories/Pfizer/Sanofi/Yakult Honsha
Alternative Names: 1 OHP; 1670 RB7; Ai Heng; Aiheng; Dacotin; Dacplat; Diaminocyclohexane oxalatoplatinum; Eloxatin; Eloxatine; Elplat; JM-83; NSC 266046; Oxalatoplatin; Oxalatoplatinum; RP 54780; SR 96669Latest Information Update: 05 Nov 2023
At a glance
- Originator Nagoya University
- Developer Alliance for Clinical Trials in Oncology; Beth Israel Deaconess Medical Center; Chugai Pharmaceutical; Dana-Farber Cancer Institute; Debiopharm; Pfizer; Sanofi; University of California at Irvine; University of Southern California; University of Texas M. D. Anderson Cancer Center; Yakult Honsha
- Class Antineoplastics; Platinum complexes; Small molecules
- Mechanism of Action DNA cross linking agents; DNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Colorectal cancer; Gastric cancer
- Registered Liver cancer; Pancreatic cancer
- Phase II Germ cell and embryonal neoplasms; Germ cell cancer; Intestinal cancer; Oesophageal cancer; Ovarian cancer; Testicular cancer; Uterine cancer
- No development reported Head and neck cancer
- Discontinued Acute myeloid leukaemia; Breast cancer; Diffuse large B cell lymphoma; Myelodysplastic syndromes; Nasopharyngeal cancer; Non-small cell lung cancer
Most Recent Events
- 09 Sep 2022 Adverse events and efficacy data from a phase III ACHIEVE-2 trial in Colon cancer presented at the 47th European Society for Medical Oncology Congress (ESMO-2022)
- 17 Feb 2021 No recent reports on development identified - Phase-II for Head and neck cancer (Adjuvant therapy) in USA (IV) (NCT00256308)
- 31 May 2019 National Cancer Institute and Jonsson Comprehensive Cancer Center plans a phase I/II trial for Pancreatic cancer (Combination therapy) in USA (IV) (NCT03970252)